Published in Immunology on October 01, 1984
Flow cytometric determination of stem/progenitor content in epithelial tissues: an example from nonsmall lung cancer and normal lung. Cytometry A (2012) 1.18
Specific (EMT6) and non-specific (WEHI-164) cytolytic activity by host cells infiltrating tumour spheroids. Br J Cancer (1987) 0.99
The effect of interferon-gamma treatment of rat tumour cells on their susceptibility to natural killer cell, macrophage and cytotoxic T-cell killing. Immunology (1988) 0.83
Separation of cells by velocity sedimentation. J Cell Physiol (1969) 8.73
Analysis of cell surfaces by xenogeneic myeloma-hybrid antibodies: differentiation antigens of rat lymphocytes. Cell (1977) 8.46
Two subsets of rat T lymphocytes defined with monoclonal antibodies. Eur J Immunol (1980) 5.98
Characteristics of human large granular lymphocytes and relationship to natural killer and K cells. J Exp Med (1981) 5.76
Identification of Ia glycoproteins in rat thymus and purification from rat spleen. Eur J Immunol (1979) 5.55
Purification with monoclonal antibody of a predominant leukocyte-common antigen and glycoprotein from rat thymocytes. Eur J Immunol (1979) 3.69
T-lymphocyte heterogeneity in the rat: separation of functional subpopulations using a monoclonal antibody. J Exp Med (1978) 3.20
The roles of host and donor cells in the rejection of skin allografts by T cell-deprived rats injected with syngeneic T cells. Eur J Immunol (1982) 2.48
On the heterogeneity of murine natural killer cells. J Exp Med (1981) 2.15
Natural killer (NK) cell activity in the rat. I. Isolation and characterization of the effector cells. J Immunol (1981) 2.12
Monoclonal antibodies which distinguish between human NK cells and cytotoxic T lymphocytes. Nature (1980) 1.99
Reversible induction of natural killer cell activity in cloned murine cytotoxic T lymphocytes. Nature (1983) 1.53
Natural killer activity in the rat. II. Analysis of surface antigens on LGL by flow cytometry. J Immunol (1981) 1.51
Specificity of cell-mediated cytotoxicity against human melanoma lines: evidence for "non-specific" killing by activated T-cells. Int J Cancer (1975) 1.48
Quantitative studies of natural immunity to solid tumours in rats. Persistence of natural immunity throughout reproductive life, and absence of suppressor cells in infant rats. Immunology (1980) 1.15
Are "natural killer" cells involved in allograft rejection? Eur J Immunol (1983) 1.08
Cytotoxic Thy 1,2-positive blasts with NK-like target selectivity in murine mixed lymphocyte cultures. J Immunol (1979) 1.01
Lymphoid cell subclasses in rejecting renal allograft in the rat. Cell Immunol (1983) 0.98
Mononuclear-cell infiltration in ovarian cancer. III. Suppressor-cell and ADCC activity of macrophages from ascitic and solid ovarian tumours. Br J Cancer (1982) 0.97
Quantitation of proliferative and cytotoxic precursor cells directed against human tumours: limiting dilution analysis in peripheral blood and at the tumour site. Int J Cancer (1982) 0.97
Detection of either rapidly cytolytic macrophages or NK cells in "activated" peritoneal exudates depends on the method of analysis and the target cell type. Immunology (1981) 0.94
The specificity of rat natural killer cells and cytotoxic macrophages on solid tumor-derived target cells and selected variants. J Immunol (1981) 0.87
A comparison of membrane markers on rat cytotoxic cells. Immunology (1983) 0.87
The induction of cytotoxic macrophages and natural killer cells in congenitally athymic rnu/rnu rats. Cell Immunol (1980) 0.86
Natural killer cells infiltrate transplanted chemically induced sarcomas. Cell Immunol (1981) 0.84
Systemic and in situ natural killer and suppressor cell activities in mice bearing progressively growing murine sarcoma-virus-induced tumors. Int J Cancer (1981) 0.82
Role of T-lymphocyte subsets in tumor rejection: implications for developing biological response modifiers and monitoring tumor--host interactions during tumor development. J Biol Response Mod (1983) 0.80
Blocking of lymphocyte-mediated cytotoxicity for rat hepatoma cells by tumour-specific antigen-antibody complexes. Nat New Biol (1972) 4.04
Single step separation of human T and B cells using AET treated srbc rosettes. J Immunol Methods (1976) 3.41
A phase I/II study of trichosanthin treatment of HIV disease. AIDS (1990) 2.26
Demonstration of tumour-specific humoral antibody against aminoazo dye-induced rat hepatomata. Br J Cancer (1967) 2.23
The influence of tumour cell DNA abnormalities on survival in colorectal cancer. Br J Surg (1985) 2.20
Over-diagnosis of hydatidiform mole in early tubal ectopic pregnancy. Histopathology (2001) 2.06
Tumour-specific immunity against spontaneous rat tumours. Int J Cancer (1966) 1.83
Demonstration of cell-surface antigens on chemically induced tumors. Ann N Y Acad Sci (1971) 1.78
A monoclonal antibody, NCRC-11, raised to human breast carcinoma. 1. Production and immunohistological characterization. Histopathology (1984) 1.72
Radioimmunodetection of human colorectal cancers by an anti-tumour monoclonal antibody. Lancet (1982) 1.71
Tumour-specific antigenicity of aminoazo-dye-induced rat hepatomas. Int J Cancer (1967) 1.62
Antitumour reactions of monoclonal antibody against a human osteogenic-sarcoma cell line. Br J Cancer (1981) 1.61
Influence of BCG infection on growth of 3-methylcholanthrene-induced rat sarcomas. Rev Eur Etud Clin Biol (1971) 1.60
Randomized double-blind phase II survival study comparing immunization with the anti-idiotypic monoclonal antibody 105AD7 against placebo in advanced colorectal cancer. Br J Cancer (2001) 1.56
Characterization of cytotoxic spleen cells and effects of serum factors in a syngeneic rat tumour system. Br J Cancer (1976) 1.53
Silver-binding nucleolar organizer regions (AgNORs) in benign and malignant breast lesions: correlations with ploidy and growth phase by DNA flow cytometry. J Pathol (1989) 1.51
Circulating prostate specific antigen-positive cells correlate with metastatic prostate cancer. Br J Urol (1992) 1.50
BCG immunotherapy of a rat sarcoma. Br J Cancer (1973) 1.50
Inhibition of hepatoma-immune lymph-node cell cytotoxicity by tumour-bearer serum, and solubilized hepatoma antigen. Int J Cancer (1973) 1.49
BCG immunotherapy of pulmonary growths from intravenously transferred rat tumour cells. Br J Cancer (1973) 1.49
Cellular and humoral immunity to rat hepatoma-specific antigens correlated with tumour status. Int J Cancer (1973) 1.48
Calcium/calmodulin regulation of the proliferation of human epidermal keratinocytes, dermal fibroblasts and mouse B16 melanoma cells in culture. Br J Dermatol (1988) 1.47
Leukocyte origin and profile in follicular aspirates at oocyte retrieval. Hum Reprod (2005) 1.41
Solubilization of tumour-specific antigen from plasma membrane of an aminoazo-dye-induced rat hepatoma. Clin Exp Immunol (1972) 1.41
Direct ex vivo comparison of the breadth and specificity of the T cells in the liver and peripheral blood of patients with chronic HCV infection. Eur J Immunol (2001) 1.40
Vaccination therapy in malignant disease. Surgeon (2006) 1.40
Studies on the immunobiology of rnu/rnu "nude" rats with congenital aplasia of the thymus. Eur J Immunol (1980) 1.36
Preparation and properties of a drug-carrier-antibody conjugate showing selective antibody-directed cytotoxicity in vitro. Int J Cancer (1983) 1.35
Immunoreactivity by intrinsic lymphoid cells in colorectal carcinoma. Br J Cancer (1979) 1.35
Immunological aspects of chemical carcinogenesis. Adv Cancer Res (1973) 1.31
Neoantigens on spontaneous and carcinogen-induced rat tumors defined by in vitro lymphocytotoxicity assays. Int J Cancer (1974) 1.30
Immunocytochemical staining of breast carcinoma with the monoclonal antibody NCRC 11: a new prognostic indicator. Br Med J (Clin Res Ed) (1985) 1.29
BCG immunotherapy of rat tumours in athymic nude mice. Nature (1975) 1.27
Immunological and structural features of the protein core of human polymorphic epithelial mucin. Mol Immunol (1990) 1.27
Systemic cytokine levels and the effects of etanercept in TNF receptor-associated periodic syndrome (TRAPS) involving a C33Y mutation in TNFRSF1A. Rheumatology (Oxford) (2005) 1.26
Phenotype of rat natural killer cells defined by monoclonal antibodies marking rat lymphocyte subsets. Immunology (1982) 1.25
Evaluation of immunoreactivity with monoclonal antibody NCRC 11 in breast carcinoma. Br J Cancer (1987) 1.23
Isolation of membrane-associated tumour-specific antigen from an aminoazo-dye-induced rat hepatoma. Int J Cancer (1969) 1.21
Interleukin-8 and inducible nitric oxide synthase mRNA levels in inflammatory bowel disease at first presentation. J Pathol (1997) 1.21
Detection and isolation of tumour-specific antigen associated with a spontaneously arising rat mammary carcinoma. Int J Cancer (1970) 1.20
Immunogenic properties of rat hepatoma subcellular fractions. Br J Cancer (1974) 1.20
Embryonic antigen expression on experimental rat tumours. Transplant Rev (1974) 1.20
Demonstration by colony inhibition methods of cellular and humoral immune reactions to tumour-specific antigens associated with aminoazo-dye-induced rat hepatomas. Int J Cancer (1971) 1.19
Human monoclonal anti-idiotypic antibody to the tumour-associated antibody 791T/36. Immunology (1989) 1.18
A monoclonal antibody against human colonic adenoma recognizes difucosylated Type-2-blood-group chains. Biosci Rep (1983) 1.18
Detection of circulating hepatoma D23 antigen and immune complexes in tumour bearer serum. Br J Cancer (1973) 1.17
Association between clinical symptoms and lymphocyte abnormalities in a population with chronic domestic exposure to industrial solvent-contaminated domestic water supply and a high incidence of leukaemia. Cancer Immunol Immunother (1988) 1.17
Embryonic antigen expression in chemically induced rat hepatomas and sarcomas. Int J Cancer (1972) 1.17
Inhibition of lymphocyte cytotoxicity for human colon carcinoma by treatment with solubilized tumour membrane fractions. Int J Cancer (1973) 1.16
Enhanced cell-mediated tumor killing in patients immunized with human monoclonal antiidiotypic antibody 105AD7. Cancer Res (1994) 1.15
Quantitative studies of natural immunity to solid tumours in rats. Persistence of natural immunity throughout reproductive life, and absence of suppressor cells in infant rats. Immunology (1980) 1.15
Bisphosphonates induce apoptosis in mouse macrophage-like cells in vitro by a nitric oxide-independent mechanism. J Bone Miner Res (1996) 1.15
Antitumor immune response and interleukin 2 production induced in colorectal cancer patients by immunization with human monoclonal anti-idiotypic antibody. Cancer Res (1991) 1.14
Circulating immune complexes in patients with breast cancer. Br Med J (1977) 1.14
Clinical outcome of colorectal cancer patients treated with human monoclonal anti-idiotypic antibody. Int J Cancer (1994) 1.13
Studies on the microcytotoxicity test. II. The uptake of amino acids ([3H]leucine or [75Se]methionine) but not nucleosides ([3H]thymidine or [125I]IUdR) or 51CrO24-provides a direct and quantitative measure of target cell survival in the presence of lymphoid cells. J Immunol Methods (1978) 1.13
BGG immunotherapy of local subcutaneous growths and post-surgical pulmonary metastases of a transplanted rat epithelioma of spontaneous origin. Int J Cancer (1973) 1.13
Characteristics of a cell surface antigen defined by an anti-human osteogenic sarcoma monoclonal antibody. Eur J Cancer Clin Oncol (1983) 1.12
Human myeloma cells shed the interleukin-6 receptor: inhibition by tissue inhibitor of metalloproteinase-3 and a hydroxamate-based metalloproteinase inhibitor. Br J Haematol (1998) 1.11
Immune response to a syngeneic rat tumour: development of regional node lymphocyte anergy. Br J Cancer (1973) 1.11
Modification of the immunogenicity and antigenicity of rat hepatoma cells. I. Cell-surface stabilization with glutaraldehyde. Br J Cancer (1979) 1.09
Kinetics of divalent monoclonal antibody binding to tumour cell surface antigens using flow cytometry: standardization and mathematical analysis. Mol Immunol (1985) 1.09
Fractionation of plasma membrane-associated tumor-specific antigen from an aminoazo dye-induced rat hepatoma. Int J Cancer (1973) 1.08
The characteristics of blood-borne radiolabels and the effect of anti-mouse IgG antibodies on localization of radiolabeled monoclonal antibody in cancer patients. J Nucl Med (1985) 1.07
DNA in meningioma tissues and explant cell cultures. A flow cytometric study with clinicopathological correlates. J Neurosurg (1987) 1.07
c-myc oncogene product expression and prognosis in operable breast cancer. Br J Cancer (1989) 1.06
Association of antigen expression and DNA ploidy in human colorectal tumors. Cancer Res (1986) 1.06
BCG in tumor immunotherapy. Adv Cancer Res (1978) 1.06
Rat lymphocyte subsets: cellular requirements for the generation of T-cell growth factor. Cell Immunol (1982) 1.05
C595--a monoclonal antibody against the protein core of human urinary epithelial mucin commonly expressed in breast carcinomas. Br J Cancer (1990) 1.05
Cell-mediated and humoral immune reactions to human tumours. Int J Cancer (1973) 1.05
Immunology of spontaneously arising rat mammary adenocarcinomas. Int J Cancer (1969) 1.05
Matrix metalloproteinase 9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasia. Br J Cancer (1994) 1.04
Enhanced expression of the complement regulatory protein CD55 predicts a poor prognosis in colorectal cancer patients. Cancer Immunol Immunother (2003) 1.04
Immunohistochemical localization of Y hapten and the structurally related H type-2 blood-group antigen on large-bowel tumours and normal adult tissues. Int J Cancer (1984) 1.04
Humoral factors abrogating cell-mediated immunity in the tumor-bearing host. Curr Top Microbiol Immunol (1975) 1.04
131I and 111In-labelled monoclonal antibody imaging of primary lung carcinoma. Nucl Med Commun (1986) 1.03
Tumor antigens and tumor-host relationships. Annu Rev Med (1976) 1.03
Tumour aneuploidy, prognostic parameters and survival in primary breast cancer. Br J Cancer (1987) 1.03
Distribution of a basic azo-dye-binding protein in normal rat tissues anc carcinogen-induced hepatomata. Br J Cancer (1968) 1.03
Influence of whole body irradiation on bcg contact suppression of a rat sarcoma and tumour-specific immunity. Br J Cancer (1976) 1.02
Selective cytotoxicity against human tumour cells by a vindesine-monoclonal antibody conjugate. Br J Cancer (1983) 1.02
Estimation of DNA content in uveal melanomas by flow cytometry. Eye (Lond) (1989) 1.02